II. Department of Pediatrics, Semmelweis University, Tuzolto utca 7-9, Budapest, 1094, Hungary.
BMC Pediatr. 2021 Jul 29;21(1):331. doi: 10.1186/s12887-021-02791-0.
Neurofibromatosis type 1 (NF1), which is caused by heterozygous inactivating pathogenic variants in the NF1, has poor phenotypic expressivity in the early years of life and there are numerous conditions, including many other tumor predisposition syndromes, that can mimic its appearance. These are collectively termed NF1-like syndromes and are also connected by their genetic background. Therefore, the NF1's clinical diagnostic efficiency in childhood could be difficult and commonly should be completed with genetic testing.
To estimate the number of syndromes/conditions that could mimic NF1, we compiled them through an extensive search of the scientific literature. To test the utility of NF1's National Institutes of Health (NIH) clinical diagnostic criteria, which have been in use for a long time, we analyzed the data of a 40-member pediatric cohort with symptoms of the NF1-like syndromes' overlapping phenotype and performed NF1 genetic test, and established the average age when diagnostic suspicion arises. To facilitate timely identification, we compiled strongly suggestive phenotypic features and anamnestic data.
In our cohort the utility of NF1's clinical diagnostic criteria were very limited (sensitivity: 80%, specificity: 30%). Only 53% of children with clinically diagnosed NF1 had a detectable NF1 pathogenic variation, whereas 40% of patients without fulfilled clinical criteria tested positive. The average age at first genetic counseling was 9 years, and 40% of children were referred after at least one tumor had already been diagnosed. These results highlight the need to improve NF1-like syndromes' diagnostic efficiency in childhood. We collected the most extensive spectrum of NF1-like syndromes to help the physicians in differential diagnosis. We recommend the detailed, non-invasive clinical evaluation of patients before referring them to a clinical geneticist.
Early diagnosis of NF1-like syndromes can help to prevent severe complications by appropriate monitoring and management. We propose a potential screening, diagnostic and management strategy based on our findings and recent scientific knowledge.
神经纤维瘤病 1 型(NF1)是由 NF1 中杂合失活的致病性变异引起的,在生命的早期表现出较差的表型表达,并且有许多病症,包括许多其他肿瘤易感性综合征,可以模仿其外观。这些病症统称为 NF1 样综合征,并且它们之间也存在遗传背景的联系。因此,NF1 在儿童时期的临床诊断效率可能很困难,通常需要进行基因检测。
为了估计可能模仿 NF1 的综合征/病症的数量,我们通过广泛搜索科学文献来对其进行了汇编。为了测试长期使用的 NF1 的美国国立卫生研究院(NIH)临床诊断标准的实用性,我们分析了具有 NF1 样综合征重叠表型症状的 40 名儿科队列的患者数据,并进行了 NF1 基因检测,确定了诊断可疑性出现的平均年龄。为了便于及时识别,我们汇编了强烈提示的表型特征和病史数据。
在我们的队列中,NF1 的临床诊断标准的实用性非常有限(敏感性:80%,特异性:30%)。只有 53%的经临床诊断为 NF1 的儿童存在可检测到的 NF1 致病性变异,而 40%的未满足临床标准的患者检测结果为阳性。首次遗传咨询的平均年龄为 9 岁,40%的患儿在至少诊断出一种肿瘤后才被转介。这些结果强调了提高儿童时期 NF1 样综合征诊断效率的必要性。我们收集了最广泛的 NF1 样综合征谱,以帮助医生进行鉴别诊断。我们建议在将患者转介给临床遗传学家之前,对患者进行详细的、非侵入性的临床评估。
早期诊断 NF1 样综合征可以通过适当的监测和管理来帮助预防严重并发症。我们根据我们的发现和最新的科学知识提出了一种潜在的筛查、诊断和管理策略。